BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

This designation highlights the potential of amlenetug as a treatment option for people living with Multiple System Atrophy. We are hopeful of the potential for amlenetug to slow the clinical ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Across two cohorts, the Automated Imaging Differentiation for Parkinsonism (AIDP) machine learning model distinguished ...

This designation highlights the potential of amlenetug as a treatment option for people living with multiple system atrophy. We are hopeful of the potential for amlenetug to slow the clinical ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.